ABSTRACT
219
The mecA gene, the predominant determinant of methicillin resistance in S. aureus is very probably not native to 
223
An experimental system has been elaborated and used confirming that the resistance determinant mecA of MRSA 224 strains has evolved from S. sciuri pbpD [49] .
225
It has generally been accepted that the resistance appeared right after the mecA gene, (encoding methicillin resistance 226 carried on a SCCmec element) was horizontally transferred to an originally sensitive strain of S. aureus, and an 227 international working group (called (IWG-SCC) has been working on the classification of "Staphylococcal Cassette
228
Chromosome Elements" [50] . It was found that the intensity of antimicrobial treatments,
229
as well as the risk of transferring them to humans or human isolates, was somehow correlated [48] .
230
Many clonal lineages of MRSA, and methicillin-resistant S. epidermidis, were found circulating in hospitals,
231
suggesting that companion animals could contribute to the dissemination of highly successful human clones [51] .
232
The recently accomplished whole genome, sequencing a collection of the first MRSA isolates, followed by applied
233
Bayesian phylogenetic reconstruction, provided an option for reconstructing the evolutionary history of the archetypal
234
MRSA. It has been assumed that the approximate date at which the earliest MRSA lineage harboring the SCCmec 235 appeared, was about the mid-1940s. This time was much prior to the application of methicillin [52] . Naturally, it is 236 quite plausible to suppose that inducible enzymes play a role in the biochemical mechanisms. Consequently, the 237 resistance to a new antibiotic could not have appeared before application of a lower (not immediately fatal) dose of 238 the given compound.
239
From this important discovery, one concludes pessimistically that genomic sources of intrinsic antibiotics 
Extended spectrum β-lactamase (ESBL) producing Enterobacteriaceae and Klebsiella pneumoniae

244
The phenotype of resistance to antibiotics can result by four mechanisms: (1) enzymatic detoxification; (2) efflux;
245
(3) reduced cell wall permeability, that is a decreased affinity of the target for the antibiotic molecule; and (4) a 246 bypass of the target. β-lactams detoxification of antibiotics by β-lactamases is widespread in nearly all bacterial phyla. In
247
Gram-negative bacteria, β-lactamase production is frequently associated with reduced permeability of the outer 248 membrane and efflux [53] .
249
From an evolutionary point of view, probably the most important discovery is that the extended spectrum β-evolutionary mechanisms, leading to the appearance of other antibiotic resistant mutants, at a significantly higher 252 degree than in the normal population [54, 55] .
253
The emergence of ESBL producing Enterobacteriaceae [56] is another classical example of the threat coming from 254 multiple resistance pathogens. Klebsiella species and E. coli have most frequently caused diseases of the urinary tract, 255 biliary tract, gastrointestinal tract, and wounds due to trauma in humans. Bacteremia, hospital-acquired pneumonia,
256
postoperative meningitis, and nosocomial infections produce life-threatening diseases. The prevalence of ESBL 257 production among E. coli and Klebsiella species varies depending on geography, nature of the institution and age of 258 the population. In vitro resistance to ceftazidime, and/or aztreonam, can be used as a phenotypic marker of one of 259 these new groups of enzymes, referred to as ESBLs [56] .
260
The biochemical background is the increasing number of β-lactamase enzymes with enlarged substrate specificities.
261
The substrate range includes cephalosporins (cefotaxime and ceftriaxone) [ 
267
To overcome ESBL problems, carbapenem antibiotics were developed. They are relatively resistant to hydrolysis by 268 most β-lactamases. In some cases they act either as "slow substrate" β-lactamases inhibitors, and are capable of 
274
Since 2006, however, the number of carbapenem-resistant Enterobacteriaceae (CRE) has also significantly emerged,
275
providing a serious public health threat [83] . As for the molecular genetics, a novel, epidemic, serine class-A type 
278
As for K. pneumoniae, the primary mode of spread is clonal dissemination, while that for E. coli and other
279
Enterobacteriaceae species is polyclonal dissemination. Several alleles, promoters and carriers localized on mobile 280 genetic elements, have been identified [86] . Since the above mentioned review, in the carbapenem-resistant K.
281
pneumoniae population, colistin resistance has also appeared [87].
282
As for future perspectives, an important question is what is the role of antibiotic resistance from the aspect of a 283 given pathogenic species. Is it axiomatic that antibiotic resistance is a positive selection factor?
284
Recent population dynamics analysis, carried out by using comparative intra-species genomics to analyze a 285 systematic decade-long survey of the most successful lineages within a broader E. coli population associated with 286 disease in England, led to the unexpected conclusion that that multi-drug resistance was not the dominant reason for 287 (evolutionary) prevalence of E. coli lineages in this population [88] . The most frequently identified lineage, (ST73),
288
was susceptible to most antibiotics, while the virulent, globally disseminated, multi-drug-resistant, lineage (ST131)
289
was much less successful! The conclusion was that E. coli lineages in invasive diseases have been driven by negative 290 frequency-dependent selection occurring outside of the hospital, most probably in the commensal niche where the 291 drug resistance is not necessarily a primary determinant of success [88] .
292
The reviewers suppose that maybe an uptake of a mobile genetic element, or a plasmid, means a genetic load acting 293 as a negative determinant of the success. 
295
Armored with a full arsenal of persistence (Biofilm Formation), and resistance (Genome Plasticity),
296
P. aeruginosa is one of the two pangenomic Gram-negative pathogenic species acquiring an extraordinarily large 
347
The availability of whole-genome sequencing offers a challenging option for resistance surveillance via the resistome 348 (i.e. the genes and mutations underlying antibiotic resistance), especially in bacteria species owning a large pan-genome, 
362
The reviewers wondered whether it would ever be possible to forecast invoked defense mechanisms to in silico 363 designed antimicrobial peptides on the basis of information provided by full-genome sequences. 
376
The Acinetobacter species are rod-shaped, glucose-non-fermentative, non-motile, non-fastidious, catalase-positive,
377
oxidative-negative, aerobic, Gram-negative coccobacilli. Acinetobacter baumannii is the only member of the
378
Moraxellaceae to lack cytochrome C oxidases, and it can cause serious diseases in plants, animals and humans
379
[118].
380
Since Acinetobacter species have been discovered, as avirulent group of bacteria (32 years ago) taxonomic relations of 
399
To keep track, and not be lost in the jungle of relevant literature, we relied mainly on two excellent previous reviews 400 written by Antunes [120] and Lee [128] with their associates, respectively, and used them as "beacon-of-lights".
401
The species A. baumannii used to have a low phylogenetic diversity, providing a severe evolutionary bottle-neck 402 through which a micro-evolutionary tree of many branches has emerged since the late 1980s [120, 128] 
424
Acinetobacter baumannii has a number of resistance mechanisms, including β-lactamases, aminoglycoside-modifying 
428
The most up-to-date reviews about the biology, virulent factors and antibiotic resistance problems demonstrate the 429 extreme rapid evolution of multi-drug resistance of the species, allowing science to discover many new mechanisms 430 and strategies. Herein we just make a short summary of the resistance mechanisms, mainly based on the two 
446
One report from India showed that blaOXA-51 and blaOXA-23 were present in all 103 carbapenem-resistant A. 
463
As for efflux pumps, the resistance-nodulation-division efflux pump superfamily is represented by 3 members in A. 
472
furthermore erythromycin, acriflavine, benzalkonium chloride, and methylviologen) [197] , and finally, AbaF
473
(responsible for fosfomycin resistance) [198] .
474
Multi-drug and toxic compound extrusion family represented by AbeM is responsible for resistance to imipenem 
477
The EmrAB-TolC efflux pump is also present in A. baumannii and responsible for resistance to netilmicin, 
490
Alteration of target sites is the resistance mechanism materialized by modifications in antibiotic target sites in A.
491
baumannii. Alteration of target sites seems to be a successful mechanism against almost all antibiotics tested so far.
492
Imipenem resistance could be the phenotypic consequences of overexpression of altered penicillin-binding proteins
493
(PBPs), which have a low affinity for imipenem [209] .
494
Aminoglycoside resistance could be the phenotypic consequences of the 16S rRNA methylase (ArmA) activity, found in 
533
The type strain (ACICU), representing the ICL2 global clone, also contains a homolog to AbaR1, but it is much 534 smaller (seven antibiotic resistance coding genes). In this strain, drug resistance is more evenly distributed 
544
Enterococcus is a large genus of lactic acid bacteria that are Gram-positive cocci that often occur in pairs or short 545 chains, and are difficult to distinguish from streptococci on physical characteristics alone. The pathogenic strains cause 546 infections, including urinary tract infection (UTIs), endocarditis, bacteremia, catheter-related infections, wound 547 infections, and intra-abdominal and pelvic infections (Wikipedia).
548
The MDR enterococci are important nosocomial pathogens, and a growing clinical challenge, because they developed 
649
The whole-genome sequencing procedure, comparing the parental (D344S) and the various mutant M9 strains was 
737
The three enzymes displayed similar catalytic activities in the absence of drugs. However, the resistant mutations 
745
In fact, reports have also suggested a possible contribution of multi-drug efflux pumps to FQ resistance in B. 
752
The authors discovered a novel "mutation hot spot" (GBAA0834) that leads to the increased expression of multi- 
776
Fortunately enough, there is no sign of the occurrence of multi-drug resistant F. tularensis strains, but resistances to 777 the same antibiotics used in its treatment are known in other bacteria, so acquired resistance could be forecast.
778
Furthermore, aminoglycosides, quinolones, chloramphenicol and tetracyclines are important, bearing in mind the 779 side effects and probability to replace them. This is why it is important to be informed about the general picture of the 
827
This mini-review unfortunately could not avoid facing and conflicting with the Lamarckian concept, but we think that 828 these little collisions could, or more accurately should, be clarified. One collision point is related to the term of 829 "acquired resistance", the consequence of taking up a plasmid with a mobile element harboring an antibiotic 830 resistance cassette. It is naturally "acquired" and also inherited. This is a proof of the Darwinian (and not the 
Tolerance, persistence & resistance 837
The efforts of better understanding, and attempts at understanding either the intrinsic or environmental conditions behind 
839
A new and promising approach to search for potent antibiotics, which may not provoke resistance in pathogen targets, 
854
We found the best definition in the literature for distinguishing between resistance and tolerance in the excellent 
859
The biochemical mechanism behind persistence has mostly been revealed in the last 7 years. A second messenger 860 molecule, ppGpp, plays a key role by mediating in activating Type I and II Toxin-Antitoxins [301, 302]. However, 861 the evolution of tolerance is much less understood than that of resistance.
862
There were two extremely important publications that came out of the Laboratory of Dr. Nathalie Q. Balaban (Racah
863
Institute of Physics, The Sudarsky Center for Computational Biology and the Center for NanoScience, Edmond J.
864
Safra Campus, The Hebrew University, Jerusalem, Israel) on comparing the evolutionary processes of antibiotic 865 resistance and tolerance [300, 303] . These led to the recent discovery that the mechanisms of tolerance and 866 resistance are not simply "mechanistically distinct" [304] , but somehow are also interrelated, since tolerance 867 frequently precedes resistance. These two outstanding experiments are definitely worthwhile to discuss in a little 868 more detail.
869
In the first, the authors followed the evolution of E. coli populations under intermittent exposures to rather high 870 concentrations of ampicillin, still comparable to therapeutic doses, and separated by intervals in fresh medium
871
[300]. They found the cultures became tolerant to ampicillin by acquiring mutations that extended their lag phase (i.e., 872 the period before exponential growth is resumed after the stationary phase), without any change in the sensitivity to resistance. The authors characterized the evolved strains from the aspects of both resistance and tolerance. They 875 found that each selected strain adapted by specific mutations, which were ultimately fixed in their evolved 876 populations. They monitored the phenotypic changes at both the population and single-cell levels. They found the first 877 adaptive change to antibiotic stress was the development of tolerance through a major adjustment in the distribution 878 of the single-cell lag-time, without a change in resistance. Surprisingly enough, they observed that the lag time of 879 bacteria before starting to propagate again was optimized to match the duration of the antibiotic-exposure interval. The 880 authors identified the mutants, and named them "tolerance by lag" (tbl), of target genes involved in this "antibiotic-881 driven" phenotype. It benefited from the whole genome-sequencing of each evolved strain, and restored the respective 882 wild-type alleles. They concluded that a "better understanding of lag-time evolution as a key determinant of the 883 survival of bacterial populations under high antibiotic concentrations", could lead to new approaches to block the 884 evolution.
885
In the second effort to learn whether persistent and resistant phenotypes were genetically somehow coupled, another 886 excellent in vitro evolution experiment was carried out [303] . The authors of this paper applied a lower dose of 887 ampicillin, which was still comparable to the therapeutic dose, separated by intervals in fresh medium, and had a 
915
The results of this interesting experiment indirectly explain why it was previously possible to isolate highly persistent 
920
We concluded that the hypothesis is based on increasing evidence suggesting that persistence triggered and enabled 921 by a network of intracellular stress responses can accelerate the processes of adaptive evolution beyond shedding 922 light on the basis of persistence. Those persisters could be an evolutionary reservoir from which resistant organisms 923 can emerge [307] is probably correct, but there is not any direct genetic link between tolerance and resistance so far.
924
Whatever was the philosophy behind it, the first antibiotic (teixobactin) found in a screen of uncultured bacteria, which 
931
In fact, teixobactin is the only antibiotic in the literature without detectable resistance. It is a NRP (non-ribosomal),
932
peptide-like, enzymatically synthetized, molecule. The teixobactin gene cluster has only been predicted [308] .
933
This publication was commented on by several authors (published as #65059 in the same issue of Nature) [308] .
934
Draper (2015) warned that a broader variety of resistance mechanisms might be expected to be revealed in future
935
clinical settings, such as the appearance of a special reductase. 
939
It is obvious that antibiotic resistance is an evolutionary process, based on sequential accumulation of multiple 940 mutations, under selective conditions. This part of the evolution can experimentally be studied, or even recapitulated.
941
The genetic variability in nature, or in a hospital, could be enlarged by horizontal gene transfer mediated by 
960
As we saw, in the "war" against antibiotic resistance, we have just been losing battle after battle. As mentioned before, 
MDR Revolution in genus Enterococcus 999
Enterococcus cecorum, a normal commensal intestinal inhabitant, is increasingly responsible for outbreaks of 1000 arthritis and osteomyelitis in chickens worldwide. However, since 2002, E. cecorum has increasingly been 1001 recognized as a causative pathogen of enterococcal spondylitis (ES) [312] [313] [314] [315] [316] [317] [318] [319] [320] [321] [322] [323] [324] .
1002
Enterococcal spondylitis is a specific manifestation of E. cecorum-associated diseases, in which increased flock morbidity 1003 and mortality result from chronic infection involving the free thoracic vertebra and adjacent notarium or synsacrum. 
1009
ES has also been documented in broiler chickens in different countries all over the globe, in Belgium [312] 
1060
The explanation of this phenomenon is that the agrocinopine gene, which has a normal metabolic function in the 1061 nopaline biosynthesis in the wild-type strain, also pleiotropically functions as a "sensitivity" gene, making the wild- 
1076
Closing remarks 1077
In the "card game" of the antibiotics and invoked resistances many reliable investigators consider polymixin
1078
(colistin) and vancomycin as the respective last "trump" against Gram-negative and Gram positive resistant 1079 pathogens, forecasting that the appearance Gram-negative isolates of colistin-resistance and that of Gram-positive 1080 isolates of vancomycin resistance means the end of the heroic "age of antibiotics".
1081
The authors of this review have reservation for accepting this pessimistic view. We suppose that the "card game"
1082
between new antibiotics and invoked resistances has not been finished yet. The genetic sources of both intrinsic and 1083 acquired resistances in the bacteria seem to be non-exhaustible. This fact justifies 'hands-up' pessimism. Fortunately appearing resistances by discovering and introducing new, properly designed antimicrobial peptides at least for a long time. Therefore, we are expecting new antimicrobial peptides (either of natural or of synthetic origin) as new trumps 1088 as in the "card game" of science and bacterial multi-drug resistance.
1089
We propose that the options provided by the natural and synthetic antimicrobial peptides will offer new solutions.
1090
The QSAR-designed synthetic antimicrobial peptides, and the non-ribosomal (NRP) peptides, especially those 
